Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients
CAM combined with apatinib plus IRT as a second-line treatment exhibits acceptable efficacy and safety in advanced or metastatic ESCC patients. The model that combines clinical and radiomic features has the greatest ability to predict the survival of advanced or metastatic ESCC patients.
Authors
- Huiqin Luo (ORCID: https://orcid.org/0000-0001-7550-3719)
- Bing Hu (ORCID: https://orcid.org/0000-0003-4167-9083)
- Ying Yan (ORCID: https://orcid.org/0000-0001-8556-7417)
- Wenju Chen (ORCID: https://orcid.org/0000-0003-3226-7386)
- Lihong Ke
- Lulu Cao (ORCID: https://orcid.org/0009-0000-0088-5919)
- Xudong Liu (ORCID: https://orcid.org/0000-0002-6893-8842)
- Shusheng Wu (ORCID: https://orcid.org/0000-0003-1084-8630)
- Mengge Li (ORCID: https://orcid.org/0000-0003-1337-1823)
- Yifu He (ORCID: https://orcid.org/0000-0003-1990-0298)
- Chenghui Li (ORCID: https://orcid.org/0000-0002-2778-5149)
- Xiaoxiu Hu
- Huimin Li (ORCID: https://orcid.org/0000-0003-4504-9580)
- Jiayu Niu
- Gang Wang (ORCID: https://orcid.org/0000-0003-0252-488X)
Institutions
- Wannan Medical College (CN)
- University of Science and Technology of China (CN)
- Anhui Provincial Hospital (CN)
- Anqing City Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1186/s12885-025-14207-8
- Citations
- 1
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Fundamental Research Funds for the Central Universities